Ozanimod
Zeposia (ozanimod) is a small molecule pharmaceutical. Ozanimod was first approved as Zeposia on 2020-03-25. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 2, sphingosine 1-phosphate receptor 4, and sphingosine 1-phosphate receptor 3. Zeposia's patents are valid until 2030-11-15 (FDA).
Trade Name | Zeposia |
---|---|
Common Name | Ozanimod |
Indication | relapsing-remitting multiple sclerosis |
Drug Class | Immunomodulators |